Fifty fit, female patients were given four consecutive intravenous doses of etomidate 10 mg, so as to maintain sleep, after establishment of epidural block for postpartum sterilization. A matched group was given four doses of thiopentone 125 mg. Cumulative hypnotic effect, as judged by increasing sleep duration with second and subsequent doses, was much less with etomidate than with thiopentone. Etomidate did not depress blood pressure, whereas it fell progressively with successive doses of thiopentone. Injection pain was reported in 68% of patients receiving etomidate, and this tended to increase with successive doses; 12 % also showed local inflammation at the injection site. Tremor, due to etomidate, was common, but did not increase with successive doses. Feelings of sleepiness, lasting several hours after waking, were more common after thiopentone than after etomidate.
INTRODUCTION
Etomidate is a rapid-onset, short-acting intravenous hypnotic, which has been in use since 1971 (J anssen et al. 1971 ). Large-scale trials have established its safety and lack of cardiorespiratory depressive effects, but it has gained little acceptance because of the frequency with which it causes involuntary movements, and pain at the injection site (Doenicke et al. 1974 , Weymar et al. 1974 , Gooding and Corssen 1976 , Kettler et al. 1974 , Morgan, Lumley and Whitwam 1977 , Chiu and Van 1978 .
However, involuntary movements can be minimized by suitable premedication (Holdcroft et al. 1976) , and injection pain can probably be eliminated by altering the formulation of the drug (J anssen Pharmaceuticals 1976 , Kay 1976a .
Kay (197 6b) reported minimal cumulative effect of the drug in his study of 8 patients; however, no controlled study has been done of the effects of repeated doses. We therefore investigated the effects of repeated doses of etomidate, using thiopentone as a standard in a control group.
MATERIALS AND METHODS

Drug solutions
Etomidate: the commercial parenteral preparation of 2 mg/ml of the sulphate, in isotonic buffered aqueous solution (pH 3.4). Thiopentone: a freshly-prepared 2.5% solution in water (pH 11).
Patients
One hundred healthy, Chinese women presenting for postpartum sterilization under epidural analgesia, were selected for the study. Fifty received etomidate and fifty, thiopentone; the order of drug administration was randomized by drawing lots.
Anaesthetic technique
No premedication was used. On arrival in the theatre suite, an intravenous infusion of 5% dextrose in water was set up, using a 21-guage plastic cannula inserted in the dorsum of the hand or at the wrist. Lumbar epidural block was instituted, using a standard technique and a standard dose of 20 ml bupivacaine 0.5% and 5 ml lignocaine 1.5%, each with adrenaline 1/400,000 added. When the block was established, either etomidate 10 mg or thiopentone 125 mg was injected through the infusion tubing over a period of 15 seconds. A second dose of the same drug was given as soon as the patient awoke, and this was repeated until a total of four doses had been given. (If the patient remained awake after the first dose, the second was given two minutes later.) Only after waking after the fourth dose was the patient taken into the operating theatre.
Assessment
Before each lllJection, the patient was instructed to raise one arm and to keep it raised. Induction time was considered as the time elapsing between starting the injection, and the arm falling from its raised position. Blood pressure, pulse rate and respiratory rate were noted immediately before the first injection, and two minutes after sleep onset (arm drop). The patient was observed for occurrence of side effects during induction, throughout the period of sleep and during recovery. Sleep duration was considered as the interval between arm-drop and spontaneous opening of the eyes; no attempt was made to waken the patient during this time. All patients were reviewed the following day.
RESULTS
Patient characteristics
The patients' mean age was 29.1 years (S.D. 3.8 years); mean height 155 cm (S.D. 7 cm); and mean weight 54.6 Kg (S.D. 6.7 Kg). Table 1 shows the induction time for each dose of each drug. While the first dose of etomidate indu:ed sleep in 49 out of 50 patients, in the group given thiopentone, only 25 (50%) slept after the first dose. For sub:;equent doses, both drugs reliably induced sleep with an induction time of about 36 seconds. Involuntary movements, usually a fine or coarse tremor of the hands and lips, were observed in 28 (56%) of patients given etomidate, but in none of the thiopentone group. In two of the former, the movements included clonic or athetoid movements of all limb:;; in these cases the movements persisted throughout the whole period of sleep, whereas tremors usually disappeared after two or three minutes. There was no tendency for these effects to increase, either in frequency or in severity, with successive doses of etomidate. Pain during injection was reported by three patients (6%) given thiopentone, but 34 (68 %) of the etomidate group felt at least one injection to be painful; in 10 patients (20%) the pain was rated as "severe". Both the incidence and the severity of the pain tended to increase with successive doses.
Sleep induction
Inflammation at the injection site was not seen in any patients given thiopentone, but occurred in six (12 %) of the etomidate group, who developed patchy erythema extending about half-way up the lower arm proximal to the injection site. This appeared only after the second or third dose, and in two cases was accompanied by definite local urticaria. The signs resolved within an hour and in no case was there any sign of phlebitis the following day.
One patient vomited after her second dose of etomidate and was therefore excluded from the study. Two more patients were excluded because of uncertainty over their true duration of sleep, as they showed signs of waking some time bdore opening their eyes. Table 2 shows the mean sleep duration following each dose of each drug. The totalled sleep periods produced by successive doses are shown in Figures I and 2 . In the thiopentone group, those patients who did sleep following their first dose slept for a mean of 9.7 minutes, which is close to the mean for the first sleep period for the etomidate group (8.8 minutes). Sub3equent doses of thiopentone gave much longer periods of sleep (mean 32.2 minutes), but with little further increase beyond the second dose. With etomidate too, the sleep durations after the second to fourth dose were AflUt'Stllt'siL, and Intensive Care, Vu!. VI, Nv, 4, No~'emberJ 1978 similar (mean 14.3 minutes), but the increase between the first and second dose was much smaller than with thiopentone (4.9 as against 17.5 minutes).
Sleep duration
After four doses, the total period of sleep due to etomidate (mean 51.7 minutes) was only about half that produced by four doses of thiopentone (mean 10 1.4 minutes). Systolic blood pressure (BP) tended to rise slightly (mean rise 4 mm Hg) after the first dose of etomidate, but after each of the subsequent three doses, there was no significant difference from the pre-treatment level. In contrast, thiopentone tended to lower blood pressure slightly, but progressively, with each dose, so that after the first dose BP was 4 mm Hg lower than the pre-treatment level, and after the fourth dose this difference had increased to 8 mm Hg.
Diastolic blood pressure rose successively with each dose of etomidate: after the fourth dose, the mean level was 6 mm Hg above the pretreatment value. With thiopentone, mean diastolic pressure dropped by 3 mm Hg after the first dose, but after subsequent doses there was no significant difference from the pretreatment value.
Mean pulse rates did not change significantly after each dose of thiopentone. However, each dose of etomidate caused a smaIl faIl in pulse rate so that after four doses the rate was 8 beats/minute slower than the pre-treatment value, and this difference was significant (0<0.05).
Respiratory effects
Neither drug produced clinical signs of hypoventilation in any patient. Transient apnoea, immediately after induction, occurred with equal frequency in both groups (6%), and never exceeded 15 seconds. There was no difference in the incidence of coughing in the two groups (11 % ) .
Transient tachypnoea or irregularity of breathing rate was observed in six (12%) of the etomidate group; no similar effects were noted in patients given thiopentone.
There was no tendency for any of these effects to increase, either in frequency or in severitv. with repeated doses of either drug.
Lale effects
On review on the first post-operative day, 17 (34%) 8 patients given thiopentone said thev had continued to feel sleepy after return to the ward from the operating theatre, and f('iur of these (8%) felt sleepy for the rest 0f the day. In the etomidate group, only six ( 12 %) reported feeling sleepy on return to the ward. and all of them felt fuIly awake bv the ev~ning. No other symptoms or signs of late effects from either drug could be elicited.
DISCUSSION
In the search for improved intravenous hypnotics, etomidate has attracted attention because of its alleged lack of cardiodepressive effects (Doenicke et al. 1974) , absence of histamine release (Doenicke et al. 1973) , and absence of cumulative effects on repeated injection (Kay 1976a).
Our findings suggest that when etomidate is used, by repeated injections to maintain sleep for at least 50 minutes, no significant cardiovascular depression occurs in fit, young patients; nor are respiratory effects a problem. Possibly the use of opiate premedicants accounts for the small decrease in arterial pressure in the series reported by Morgan, Lumley and Whitwam (1975) . In the conditions of our study, thiopentone caused a progressive fall in blood pressure with each successive dose, whereas etomidate did not; so etomidate is probably the safer drug when cardiovascular performance is at risk.
The similarity in sleep duration between first and subsequent doses of etomidate is in marked contrast to the much more variable effects of thiopentone; in this respect etomidate is the more manageable agent for maintaining sleep by intermittent injection. Because of this discrepancy, only the initial doses can be meaningfully used to compare the potency of the two drugs as induction agents. In our patients, the first dose of etomidate at 0.2 mg/Kg was clearly more potent than the first dose of thiopentone at 2.5 mg/Kg (since only half of the thiopentone group slept after this first dose), although these doses have been taken to be equipotent (Doenicke et al. 1973, Ghonheim and Yamada 1977) .
While other side-effects of etomidate did not increase with successive doses, injection pain did, and this remains its major drawback. However, the pain is probably due not to the drug itself, but to the solvent used in its currently-marketed formulation. Kay (1976b) noted complete absence of injection pain in all 20 children who received etomidate in an alternative formulation (a solution in Cremophor EL 20%).
A discomforting finding was the 12 % incidence of local inflammation in the etomidate group, which developed only after repeated doses and was accompanied by urticarial wheals in two patients. Holdcroft et al. (1976) noted rashes in four out of 200 patients induced with etomidate. Neither in their cases, nor in ours, was there any associated bronchospasm or hypotension, and no severe allergic phenomena were reported in a trial of etomidate induction in 4,763 patients (Janssen 1976) ; but it would clearly be unwise to be complacent on this score. Further study is needed to show whether it is etomidate, or another constituent of the presently-used formulation, which is responsible for the observed local reactions. AnaesthesIa and IntensIve Care, Vol. VI, No. 4, November, 1978 
